European Human Genetics Conference, May 21–24, 2016, Barcelona, Spain  by Stuckey, Daniel W.
EBioMedicine 10 (2016) 3–4
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comIn FocusEuropean Human Genetics Conference, May 21–24, 2016,
Barcelona, SpainDaniel W. Stuckey1. Understanding Fragile X Syndrome Using Patient-derived Stem isoforms that are generated from alternately spliced transcripts of the
Cell Models
Fragile X Syndrome (FXS) is caused by an expansion of CGG trinucleotide
repeats in the 5′ untranslated region of the Fragile X mental retardation 1
(FMR1) geneon theXchromosome.Affected individuals possess over 200 cop-
ies of the CGG repeat, resulting in hypermethylation of the FMR1 promoter,
which leads to epigenetic silencing of the gene and FMRP protein deﬁciency.
Children with FXS display intellectual disabilities ranging frommild to severe,
and are often diagnosedwith autism. Intriguingly, the number of trinucleotide
repeats canvarybetweenandwithin tissuesof the same individual, a phenom-
enon known as somatic repeat instability (SRI). To elucidate the molecular
mechanisms involved in hypermethylation of CGG repeats, and to explore the
consequences of SRI, Hagar Mor-Shaked (Jerusalem, Israel) and colleagues
have developed human FXS stem cell models. Analysis of FXS-affected
human embryonic stem cell (HESC) lines showed that hypermethylation is
tightly linkedtoFMR1 transcriptional inactivation, suggesting that thisepigenet-
ic event occurs during early embryo development. Using a separate
in vitromodel, data from induced pluripotent stem cells (iPSCs) derived
from FXS patient ﬁbroblasts (FXS-iPSCs) was presented. These can be
differentiated into clinically-relevant cell types, such as neurons, while
harboring the mutations that cause the disease. Previously, exploring
the neurological features of FXS in humans relied on using difﬁcult-to-
obtain postmortem brain tissue. Neurons derived from FXS-iPSCs
open up the possibility of understanding the pathogenic mechanisms
in more detail and potentially screening drugs to reset epigenetic mod-
iﬁcations and correct the neurological phenotype.
2. Genetic Dissection ofMYO15A in Human Hereditary Deafness
Hereditary deafness is themost common inherited sensory disorder,
affecting 1 in every 1000 births. Approximately two-thirds of congenital
deafness is non-syndromic (without associated disorders) and can in-
volve mutations in an array of genes that encode proteins involved in
transducing sound into nerve signals perceived by the brain. In humans,
MYO15A encodes the unconventional myosin 15A. This actin-based
motor protein is required for transporting cargo to the tips of sensory
hairs of the inner ear called stereocilia, and their elongation. Mutations
inMYO15A cause non-syndromic autosomal recessive deafness, known
as DFNB3. Thomas B. Friedman (Bethesda, United States), presented
data elaborating on howmutations inMYO15A can cause deafness by af-
fecting stereocilia growth and function. Stereocilia produce two proteinhttp://dx.doi.org/10.1016/j.ebiom.2016.07.005
2352-3964/© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NCmouse ortholog, Myo15A, that differ by the presence (isoform I) or ab-
sence (isoform II) of a 133 kDa N-terminal domain. Using an isoform-
speciﬁc knockout mouse, stereocilia expressing only isoform II are able
to develop normal stereocilia architecture. However, as in the human sit-
uation, these mice are profoundly deaf suggesting there is a subsequent
pathology. Detailed analysis demonstrated that the two isoforms show
differential patterns of expressionwithin the stereocilia, with isoform I lo-
calizing to the tips of shorter stereocilia, whereas the taller rows express
isoform II. Indeed,mice expressing only isoform II showretraction andde-
generation of shorter stereocilia, signifying that isoform I is required for
maintenance of these structures. Theseﬁndings suggest that a therapeutic
window after birth might exist in which isoform I could be stabilized to
prevent stereocilia degeneration. Further studies are required to test
this hypothesis, but offers hope for preventing deafness in babies born
with DFNB3.
3. Genetics of Pain Sensitivity
Pain is a distressing feeling often caused by unpleasant stimulation
resulting in tissue damage, and is the most common reason for general
practitioner consultations in the developed world. Geoff Woods
(Cambridge, UK) presented the latest developments in the study of
Mendelian disorders of pain sensitivity. These disorders result from a
mutation at a single genetic locus that is inherited in families in a partic-
ular pattern. An individual might display insensitivity to pain, or con-
versely increased pain perception, depending on the consequence of
the causativemutation. The aim is to attribute mutations to speciﬁc dis-
orders by sequencing the DNA of affected families, enabling insight into
themolecularmechanisms that lead to the disease phenotype.Many ac-
quired pain syndromes occur through mutations in ion channels that
are expressed on nociceptors. Nociceptors are sensory neurons that de-
tect stimuli that have the potential to cause tissue injury such as
extremes of temperature, chemical irritants and mechanical damage.
The exact function of a given nociceptor will depend on the type and
distribution of ion channels that are expressed, and this heterogeneity
enables an appropriate response to a range of sensory inputs. For exam-
ple, voltage-gated sodium channels (Nav) allow extracellular Na+ to
pass into the interior of the neuron, which can result in an action poten-
tial. In humans, mutations in the Nav1.7, encoded by SCN9A, can cause
congenital insensitivity to pain if a null mutation prevents the passage
of Na+ into the cell. Conversely, if an activating mutation is present, this-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the cell. This can result in disorders such as inherited erythromelalgia
(IEM), causing chronic pain in the hands and feet. Recent developments
in drugs that selectively block Nav1.7 can elicit a reversal of the pain phe-
notype in humans with IEM. It is hoped that subtype-speciﬁc blockade of
other sodium channelsmight prove an effective approach to treat a range
of pain perception disorders.
4. Consequences of PPA2 Mutations
In a session dedicated tometabolic andmitochondrial disorders, two
talks focused on disorders associated with mutations in the mitochon-
drial inorganic pyrophosphatase (PPA2). PPA2 is an enzyme that
catalyzes the hydrolysis of inorganic phyrophosphate (PPi) to twophos-
phate ions, resulting in the liberation of 19 kJ. This reaction is coupled to
many energetically unfavourable reactions to drive them to completion,
for example in the metabolism of lipids. Mitochondria produce the ma-
jority of the energy required by a cell, and consequently contain ~90% of
cellular PPi. Therefore mutations that affect the function of this enzyme
can cause huge problems, especially in tissues that have high energy re-
quirements such as the heart. Kit Doudney (Christchurch, NewZealand)
presented data on four families with a spectrum of cardiomyopathy
disorders. Next-generation sequencing technologies identiﬁed muta-
tions in the PPA2 gene that were responsible for a number of neonatal
cardiac-related medical conditions including lactic acidosis and heart
failure. In one family with acute sensitivity to alcohol, two brothers
died at 15 and 20 years of age. Sequencing results revealed that both sib-
lings had inherited compound mutations, one in the catalytic site and
the other affecting a residue potentially involved in the dimerization
of PPA2. Functional studies in E. coli demonstrated that this combination
of mutations caused PPA2 to work inefﬁciently, with catalytic activity
reduced by ~70%. However, this reduction is less than the 95% activity
loss observed with purely catalytic mutations present in the majority
of affected families. The small increase in PPA2 activity associated with
the dimerizing proline228 mutation may explain the later age of onset
associated with cardiac failure in this family. The surviving siblings
also inherited these homoplastic sequence variants in PPA2, and were
subsequently ﬁtted with artiﬁcial pacemakers to counter cardiac ar-
rhythmias. Anne Guimier (Paris, France), then presented data on two
families with recurrent sudden unexpected death in infancy (SUDI).
SUDI is the most common case of post-natal infant mortality in devel-
oped countries, although the underlying cause is largely unexplained.
All babies from these families died of cardiac arrest at 4–20 months.
When post-mortem tissue was analyzed by whole exome sequencing,
compound heterozygous missense variations in the PPA2 gene were
identiﬁed. Both studies reveal new links with PPA2 and human disor-
ders, which may have implications for undiagnosed individuals with
mutations in this gene.
5. CRISPR Cas9 Tips and Tricks
Dario Lupianez and Malte Spielmann (Berlin, Germany) held an en-
gaging workshop titled CRISPR Cas9 tips and tricks. The aim was to
demonstrate how this genome editing technology can be utilized in em-
bryonic stem cells (ESCs) to produce genomic structural variations
(SVs) in mice within ten weeks. This process would typically take ayear using conventional targeting technologies, thus offering a fast al-
ternative. SVs include deletions, inversions and duplications of genomic
regions, allowing one to functionally assess gene and enhancer regions
and createmousemodels of human disease efﬁciently andwith relative
ease. This was exempliﬁed by creating mouse mutants in which
the Epha4 locus was manipulated to produce multiple pathogenic vari-
ations in the limb. Genomic deletions in regulatory regions resulted in
brachydactyly, inversions resulted in F-syndrome (syndactyly) and du-
plications produced polydactyly in mice. In all cases, the mouse pheno-
types recapitulated those of rare limb malformations in humans,
enabling the in vivo and in vitro dissection of genetic variants seen in a
clinical setting. This workshop comprised an interactive demonstration
of single guide RNA (sgRNA) design, with tips on how best to maximize
on-target activity with the targeting sequence while minimizing off-
target activity. The pitfalls of this technology were also highlighted,
including the extensive variability in targeting efﬁciency from one
locus to another and increasing the proportion of homology-directed re-
pair (HDR), over error-prone nonhomologous end joining (NHEJ), dur-
ing precise genome-editing. Strategies to increase HDR relative to NHEJ
were discussed and included the use of chemical inhibitors to target the
NHEJ pathway to favor HDR. As CRISPR Cas9 technology is reﬁned fur-
ther, modeling genomic rearrangements to understand human disease
will become increasingly powerful.6. Antisense Therapy to Treat Spinal Muscular Atrophy
Richard Finkel (Florida, USA) reported on results from a Phase II clin-
ical trial in which antisense therapy had been used to treat infantile-
onset spinal muscular atrophy (SMA). SMA is caused by a genetic defect
in the SMN1 gene, leading to reduced levels of SMN, a protein required
for the survival of motor neurons. This results in a variety of symptoms
comprising progressive muscle weakness and feeding and breathing
failure in the most severe cases. SMA is the most common genetic
cause of infant death. Although SMA patients are unable to generate
fully functioning SMN protein from SMN1, they all retain at least one
copy of the SMN2 gene. Due to a single nucleotide mutation, the major-
ity of SMN2 transcripts are alternatively spliced producing a truncated
protein that is rapidly degraded. However, a small amount of full-
length protein is produced, allowing some neurons to survive and func-
tion to some extent. One therapeutic strategy is to ﬁnd splicingmodula-
tors that can promote the inclusion of Exon 7 in SMN2, usually excluded
during splicing, to produce more of the fully functional SMN protein. In
theory, this approach would increase the total amount of functional
SMN, and thereby preserve a greater proportion of motor neurons. To
test this hypothesis, companies have used a high throughput approach
to test splicingmodulators that are able to achieve such a result, produc-
ing functional beneﬁt in preclinical models. In an open label Phase II
study sponsored by Ionis Pharmaceuticals, 20 pre-symptomatic new-
borns were treated with intrathecal administration of an antisense oli-
gonucleotide (ASO) called Nusinersen (NCT01839656). Three babies
died following enrollment. However, the remaining infants continuing
the trial are now N2 years old,many on partial or no ventilation support,
and display unprecedented improvement in motor milestones and
function. These encouraging results have informed a Phase III trial in in-
fants and children with SMA.
